Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Doris Apt"'
Autor:
Johann S. de Bono, Howard A. Burris, Jennifer O. Lauchle, Joseph A. Ware, Hartmut Koeppen, Jill M. Spoerke, Jill O. Fredrickson, Ru-Fang Yeh, Doris Apt, Martijn P. Lolkema, Marjorie G. Zauderer, Tanguy Y. Seiwert, Lee M. Krug, Hedy L. Kindler, Johanna C. Bendell, Andrew J. Wagner, Saoirse O. Dolly
Purpose: This first-in-human phase I trial assessed the safety, tolerability, and preliminary antitumor activity of apitolisib (GDC-0980), a dual inhibitor of class I PI3K, and mTOR kinases.Experimental Design: Once-daily oral apitolisib was administ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b3b50c179f79132800687cbfc8bbf93
https://doi.org/10.1158/1078-0432.c.6523982.v1
https://doi.org/10.1158/1078-0432.c.6523982.v1
Autor:
Johann S. de Bono, Howard A. Burris, Jennifer O. Lauchle, Joseph A. Ware, Hartmut Koeppen, Jill M. Spoerke, Jill O. Fredrickson, Ru-Fang Yeh, Doris Apt, Martijn P. Lolkema, Marjorie G. Zauderer, Tanguy Y. Seiwert, Lee M. Krug, Hedy L. Kindler, Johanna C. Bendell, Andrew J. Wagner, Saoirse O. Dolly
Supplementary Table 1. Dose reductions and discontinuations in stage 2 Supplementary Table 2. Pharmacokinetic parameters of apitolisib Supplementary Table 3. Summary of radiological responses at the recommended phase 2 doses of 40mg and 30mg 28/28 da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00bd1755459ba4022d78329e6a9285dd
https://doi.org/10.1158/1078-0432.22458530.v1
https://doi.org/10.1158/1078-0432.22458530.v1
Autor:
Ingrid A. Mayer, Jill M. Spoerke, Sara Cresta, Steve Gendreau, Hans Wildiers, Patrick Schöffski, Isabelle Rooney, Doris Apt, Eric P. Winer, Mark R. Lackner, Kari M. Morrissey
Publikováno v:
Cancer Research. 75:P5-19
Background: GDC-0941 is a potent and selective oral inhibitor of class I PI3K kinases that demonstrates broad activity in diverse xenograft cancer models and increases the anti-tumor activity of taxanes, associated with increased apoptotic cell death
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::025ba1feb15c928b5a9c29653020eca9
https://doi.org/10.1158/1538-7445.sabcs14-p5-19-10
https://doi.org/10.1158/1538-7445.sabcs14-p5-19-10
Autor:
Jean C-C. Chang, Randal Ong, Margaret Neighbors, Juha Punnonen, Steven R. Leong, Isabelle Sipos-Solman, Alice M. Brinkman, Doris Apt
Publikováno v:
Journal of Immunotherapy. 31:644-655
Immunization against tumor-associated antigens is a promising approach to cancer therapy and prevention, but it faces several challenges and limitations, such as tolerance mechanisms associated with self-antigens expressed by the tumor cells. Costimu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b36131dbc3a72207cdd3e6449f7b6343
https://doi.org/10.1097/cji.0b013e3181826d89
https://doi.org/10.1097/cji.0b013e3181826d89
Autor:
Lee M. Krug, Howard A. Burris, Hartmut Koeppen, Johanna C. Bendell, Tanguy Y. Seiwert, Saoirse Dolly, Martijn P. Lolkema, Ru Fang Yeh, Marjorie G. Zauderer, Andrew J. Wagner, Doris Apt, Hedy L. Kindler, Joseph A. Ware, Johann S. de Bono, Jennifer O. Lauchle, Jill Fredrickson, Jill M. Spoerke
Publikováno v:
Clinical Cancer Research, 22(12), 2874-2884. American Association for Cancer Research Inc.
Purpose: This first-in-human phase I trial assessed the safety, tolerability, and preliminary antitumor activity of apitolisib (GDC-0980), a dual inhibitor of class I PI3K, and mTOR kinases. Experimental Design: Once-daily oral apitolisib was adminis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a9f6e915271a68e44b45291a59dc13b
https://pubmed.ncbi.nlm.nih.gov/26787751
https://pubmed.ncbi.nlm.nih.gov/26787751
Overcoming antigenic diversity and improving vaccines using DNA shuffling and screening technologies
Publikováno v:
Expert Opinion on Biological Therapy. 4:589-597
Viral, bacterial and parasitic pathogens have evolved multiple strategies to evade the immune response, facilitate transmission and establish chronic infections. One of the underlying strategies that pathogens have evolved is antigenic variation of i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7975dceffbabf1be5ef6aa5c36780516
https://doi.org/10.1517/14712598.4.4.589
https://doi.org/10.1517/14712598.4.4.589
Publikováno v:
Nucleic Acids Research. 22:3825-3833
Previous studies of the epithelial specificity of the human papillomavirus type 16 (HPV-16) enhancer pointed out an important role of nuclear factor I (NFI). In epithelial cells, NFI proteins are derived from the NFI-C gene and referred to as NFI/CTF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92821b675c5763d97c16d36b17855f42
https://doi.org/10.1093/nar/22.19.3825
https://doi.org/10.1093/nar/22.19.3825
Publikováno v:
Journal of Virology. 67:4455-4463
The transcription of human papillomavirus type 16 (HPV-16) is mediated by the viral enhancer. Epithelial cell-specific activation is achieved by the cooperative interaction of apparently ubiquitous transcriptional factors. One of them, nuclear factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b418f4cb4c96760b1835e87e5f508d1
https://doi.org/10.1128/jvi.67.8.4455-4463.1993
https://doi.org/10.1128/jvi.67.8.4455-4463.1993
Publikováno v:
The Journal of biological chemistry. 272(16)
Nuclear factor I (NFI) proteins constitute a family of sequence-specific transcription factors whose functional diversity is generated through transcription from four different genes (NFI-A, NFI-B, NFI-C, and NFI-X), alternative RNA splicing, and pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc8ac34ed10d3d5b5a55fcfc4fd71d5d
https://pubmed.ncbi.nlm.nih.gov/9099724
https://pubmed.ncbi.nlm.nih.gov/9099724
Publikováno v:
Virology. 224(1)
Gene expression of human papillomavirus type 16 (HPV-16) and other HPV types is epithelial specific. Specificity is brought about by synergism between several different transcription factors that seem to occur ubiquitously but differ qualitatively an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::724b5752664755af41451634235b2063
https://pubmed.ncbi.nlm.nih.gov/8862423
https://pubmed.ncbi.nlm.nih.gov/8862423